Value Drug is alleging Alkerma conspired to delay the generic version of its Vivitrol medication used to treat opioid and ...

A drug wholesaler has sued Alkermes for allegedly maintaining an illegal monopoly over the opioid and alcohol dependence drug ...

Alkermes (NASDAQ:ALKS) is gearing up to announce its quarterly earnings on Thursday, 2024-10-24. Here's a quick overview of what investors should know before the release. Analysts are estimating that ...

RBC Capital upgraded Alkermes (ALKS) to Outperform from Sector Perform with a price target of $44, up from $42. The firm’s analysis of potential ...

Biopharmaceutical company Alkermes responded to pressure from activist investment firm Elliott Management on Thursday with a broad plan designed to boost returns.

Alkermes (NASDAQ:ALKS) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table summarizes their recent ratings, ...

AlkermesALKS stock skidded Monday — while shares of rivals Centessa PharmaceuticalsCNTA, Takeda PharmaceuticalTAK and Jazz PharmaceuticalsJAZZ rose — on the back of mixed results for its experimental ...

Jackson stated, "As we look ahead, based on our performance during the first half of the year and the expected contribution from our expanded sales efforts, we are on track to deliver record revenues ...

DUBLIN, Sept. 11, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards® program on Monday, Sept.

Jefferies increased the probability of success for ALKS-2680 to 50%, with peak sales of $1 billion, up from $700 million. The company plans to initiate a phase 2 study in patients with Narcolepsy Type ...

Alkermes is positioned for outperformance in the pharmaceutical sector due to its conservative cash-heavy balance sheet and high-margin business model. The company focuses on therapies for alcohol ...